Literature DB >> 19081591

The c-Cbl proto-oncoprotein downregulates EBV LMP2A signaling.

Masato Ikeda1, Richard Longnecker.   

Abstract

Latent membrane protein 2A (LMP2A) of Epstein-Barr virus (EBV) plays a key role in regulating viral latency and EBV pathogenesis by functionally mimicking signals induced by the B-cell receptor (BCR) altering normal B cell development. As c-Cbl ubiquitin ligase (E3) is a critical negative regulator in the BCR signal pathway, the role of c-Cbl in the function and formation of the LMP2A signalosome was examined. c-Cbl promoted LMP2A degradation through ubiquitination, specifically degraded the Syk protein tyrosine kinase in the presence of LMP2A, and inhibited LMP2A induction of the EBV lytic cycle. Our earlier studies indicated that LMP2A-dependent Lyn degradation was mediated by Nedd4-family E3s in LMP2A expressing cells. Combine with these new findings, we propose a model in which c-Cbl and Nedd4-family E3s cooperate to degrade target proteins at discrete steps in the function of the LMP2A signalosome.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19081591      PMCID: PMC2768052          DOI: 10.1016/j.virol.2008.11.018

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  41 in total

1.  WW domain HECT E3s target Cbl RING finger E3s for proteasomal degradation.

Authors:  Alessandra Magnifico; Seth Ettenberg; Cuihong Yang; Jennifer Mariano; Swati Tiwari; Shengyun Fang; Stan Lipkowitz; Allan M Weissman
Journal:  J Biol Chem       Date:  2003-08-07       Impact factor: 5.157

2.  A second Epstein-Barr virus membrane protein (LMP2) is expressed in latent infection and colocalizes with LMP1.

Authors:  R Longnecker; E Kieff
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

3.  B cell antigen receptor assembly and Syk activation in the S2 cell reconstitution system.

Authors:  Thomas Wossning; Michael Reth
Journal:  Immunol Lett       Date:  2004-03-29       Impact factor: 3.685

4.  Latent membrane protein 2A, a viral B cell receptor homologue, induces CD5+ B-1 cell development.

Authors:  Akiko Ikeda; Mark Merchant; Lori Lev; Richard Longnecker; Masato Ikeda
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

5.  Cbl-mediated degradation of Lyn and Fyn induced by constitutive fibroblast growth factor receptor-2 activation supports osteoblast differentiation.

Authors:  Karim Kaabeche; Jérome Lemonnier; Sandrine Le Mée; Joseph Caverzasio; Pierre J Marie
Journal:  J Biol Chem       Date:  2004-06-09       Impact factor: 5.157

6.  Deletion of DNA encoding the first five transmembrane domains of Epstein-Barr virus latent membrane proteins 2A and 2B.

Authors:  R Longnecker; C L Miller; B Tomkinson; X Q Miao; E Kieff
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

7.  Itchy, a Nedd4 ubiquitin ligase, downregulates latent membrane protein 2A activity in B-cell signaling.

Authors:  Akiko Ikeda; Robert G Caldwell; Richard Longnecker; Masato Ikeda
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

8.  B cell receptor signal strength determines B cell fate.

Authors:  Stefano Casola; Kevin L Otipoby; Marat Alimzhanov; Sibille Humme; Nathalie Uyttersprot; Jeffery L Kutok; Michael C Carroll; Klaus Rajewsky
Journal:  Nat Immunol       Date:  2004-02-01       Impact factor: 25.606

9.  Differentiation-associated expression of the Epstein-Barr virus BZLF1 transactivator protein in oral hairy leukoplakia.

Authors:  L S Young; R Lau; M Rowe; G Niedobitek; G Packham; F Shanahan; D T Rowe; D Greenspan; J S Greenspan; A B Rickinson; P J Farrell
Journal:  J Virol       Date:  1991-06       Impact factor: 6.549

10.  Reconstitution of interactions between tyrosine kinases and the high affinity IgE receptor which are controlled by receptor clustering.

Authors:  A M Scharenberg; S Lin; B Cuenod; H Yamamura; J P Kinet
Journal:  EMBO J       Date:  1995-07-17       Impact factor: 11.598

View more
  9 in total

1.  Rapamycin reverses splenomegaly and inhibits tumor development in a transgenic model of Epstein-Barr virus-related Burkitt's lymphoma.

Authors:  Osman Cen; Richard Longnecker
Journal:  Mol Cancer Ther       Date:  2011-01-31       Impact factor: 6.261

2.  Investigating genetic-and-epigenetic networks, and the cellular mechanisms occurring in Epstein-Barr virus-infected human B lymphocytes via big data mining and genome-wide two-sided NGS data identification.

Authors:  Cheng-Wei Li; Bo-Ren Jheng; Bor-Sen Chen
Journal:  PLoS One       Date:  2018-08-22       Impact factor: 3.240

3.  Dasatinib therapy results in decreased B cell proliferation, splenomegaly, and tumor growth in a murine model of lymphoma expressing Myc and Epstein-Barr virus LMP2A.

Authors:  Jamie L Dargart; Kamonwan Fish; Leo I Gordon; Richard Longnecker; Osman Cen
Journal:  Antiviral Res       Date:  2012-05-16       Impact factor: 5.970

4.  Epstein-Barr virus Latent Membrane Protein 2A (LMP2A)-mediated changes in Fas expression and Fas-dependent apoptosis: Role of Lyn/Syk activation.

Authors:  Ryan Incrocci; Samira Hussain; Amanda Stone; Kathryn Bieging; Lauren A C Alt; Michael J Fay; Michelle Swanson-Mungerson
Journal:  Cell Immunol       Date:  2015-08-04       Impact factor: 4.868

5.  Molecular Interactions between Two LMP2A PY Motifs of EBV and WW Domains of E3 Ubiquitin Ligase AIP4.

Authors:  Min-Duk Seo; Seung-Hyeon Seok; Ji-Hun Kim; Ji Woong Choi; Sung Jean Park; Bong-Jin Lee
Journal:  Life (Basel)       Date:  2021-04-22

6.  Viral takeover of the host ubiquitin system.

Authors:  Jean K Gustin; Ashlee V Moses; Klaus Früh; Janet L Douglas
Journal:  Front Microbiol       Date:  2011-07-28       Impact factor: 5.640

Review 7.  Epstein-Barr virus latent genes.

Authors:  Myung-Soo Kang; Elliott Kieff
Journal:  Exp Mol Med       Date:  2015-01-23       Impact factor: 8.718

8.  Spleen Tyrosine Kinase Inhibitor TAK-659 Prevents Splenomegaly and Tumor Development in a Murine Model of Epstein-Barr Virus-Associated Lymphoma.

Authors:  Osman Cen; Karuppiah Kannan; Jessica Huck Sappal; Jie Yu; Mengkun Zhang; Muzaffer Arikan; Ali Ucur; Duran Ustek; Yeter Cen; Leo Gordon; Richard Longnecker
Journal:  mSphere       Date:  2018-08-22       Impact factor: 4.389

9.  Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk.

Authors:  Dalemari Crowther-Swanepoel; Peter Broderick; Maria Chiara Di Bernardo; Sara E Dobbins; María Torres; Mahmoud Mansouri; Clara Ruiz-Ponte; Anna Enjuanes; Richard Rosenquist; Angel Carracedo; Jesper Jurlander; Elias Campo; Gunnar Juliusson; Emilio Montserrat; Karin E Smedby; Martin J S Dyer; Estella Matutes; Claire Dearden; Nicola J Sunter; Andrew G Hall; Tryfonia Mainou-Fowler; Graham H Jackson; Geoffrey Summerfield; Robert J Harris; Andrew R Pettitt; David J Allsup; James R Bailey; Guy Pratt; Chris Pepper; Chris Fegan; Anton Parker; David Oscier; James M Allan; Daniel Catovsky; Richard S Houlston
Journal:  Nat Genet       Date:  2010-01-10       Impact factor: 38.330

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.